CN105997842A - Skin external preparation comprising ginsenoside Rg1 - Google Patents

Skin external preparation comprising ginsenoside Rg1 Download PDF

Info

Publication number
CN105997842A
CN105997842A CN201610195635.0A CN201610195635A CN105997842A CN 105997842 A CN105997842 A CN 105997842A CN 201610195635 A CN201610195635 A CN 201610195635A CN 105997842 A CN105997842 A CN 105997842A
Authority
CN
China
Prior art keywords
skin
ginsenoside
psoriasin
keratin
preparation composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610195635.0A
Other languages
Chinese (zh)
Inventor
孙义东
洪勇德
李成训
裵日弘
曺恩敬
朴泌俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amore Pacific Ltd By Share Ltd
Original Assignee
Amore Pacific Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amore Pacific Ltd By Share Ltd filed Critical Amore Pacific Ltd By Share Ltd
Publication of CN105997842A publication Critical patent/CN105997842A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Abstract

The invention provides a skin external preparation comprising ginsenoside Rg1, and the ginsenoside Rg1 is capable of inhibiting psoriasin. The skin external preparation is capable of preventing and relieving skin diseases and maintaining skin moisture, wherein the skin diseases include atopic dermatitis or psoriasis. The skin external preparation is capable of preventing skin cutin forming abnormalities caused by psoriasin, preventing and relieving skin diseases and improving the skin moisture.

Description

Comprise the Dermatologic preparation composition of ginsenoside Rg1
Technical field
The present invention relates to a kind of Dermatologic preparation composition comprising ginsenoside Rg1.
Background technology
Everyone is intended to have sparkling and crystal-clear beautiful skin as baby, but skin be exposed to various During external environment condition and age increase, can gradually follow the string and impaired.Skin is straight in human body Connect the first barrier contacted with external environment condition, need the most directly to bear the stimulation that external environment condition is brought, The most small stimulation is also possible to cause sensitivity response and the change of skin.The change of this skin Change can cause generating from the most different materials, and work as interim and be routinely exposed in environmental stimulation Time, it could even be possible to cause irreversible damage.
Recently, people are actively developing a lot about a kind of i.e. psoriasin of antibacterial peptide material in skin Research.Especially it is found that psoriasin, in addition to the antibacterial action being currently known, also may be used After skin keratinocytes disdifferentiation being induced and thus causing the impaired effect of skin barrier, psoriasis Element (psoriasin) is considered as the important substance directly related with dermatosis.Grind according to actual one Study carefully result (Regine Glaser, The Journal of investigative dermatology (2009), v.129 No.3, p.641～649) it is known that representational dermatosis i.e. atopic dermatitis or psoriatic Epidermis in, it is possible to detect the psoriasin of high concentration.The skin of this psoriasin excessive concentration, Structure impaired form the finest and close, sparse can be presented, there is also what epidermal thickness thickened extremely simultaneously Phenomenon.
Additionally, the present inventor is found by the persistence research about psoriasin, apply such as ultraviolet, During the outside stimulus such as staphylococcus, tretinoin, also result in the lifting of psoriasin concentration.Additionally may be used To confirm that psoriasin can be expressed outside epidermis cell, thus to the angle egg in normal epidermal structure protein White 1 or the expression of Keratin 10 cause inhibitory action, simultaneously to causing improper epidermal differentiation and propagation The generation of protein i.e. k eratin 6 or Keratin 16 causes facilitation.Therefore by effectively suppressing Corii Bovis seu Bubali Tinea element, can obtain improving the effect of skin properties.
Prior art literature
Patent documentation
(patent documentation 1) comprises Dermatologic preparation composition (Republic of Korea's disclosure of ginsenoside Rg3 Patent 10-2014-0126892)
Summary of the invention
It is an object of the invention to provide a kind of Dermatologic preparation composition comprising ginsenoside Rg1, from And the psoriasin effect to being present in skin suppresses.
Another object of the present invention is to, by the inhibition of above-mentioned psoriasis effect, prevent and alleviate The dermatosis such as atopic dermatitis or psoriasis, and promote moisturizing power and the restoring force of skin.
To achieve these goals, the present invention provides a kind of Dermatologic preparation composition, in its effective ingredient Comprise ginsenoside Rg1, and above-mentioned ginsenoside Rg1 can suppress psoriasin.
According to embodiments of the present invention, the structure of above-mentioned ginsenoside Rg1 is as shown in following chemical formula 1:
<chemical formula 1>
According to embodiments of the present invention, the content of above-mentioned ginsenoside Rg1 is compositions overall weight 0.001～5 weight %.
According to embodiments of the present invention, above-mentioned composition comprise dermatological composition, cleansing composition with And more than one in cosmetic composition.
The compositions of the present invention can be used in prevention and alleviates dermatosis or skin moisture-keeping purpose.Now, Above-mentioned dermatosis includes atopic dermatitis or psoriasis.
The Dermatologic preparation composition comprising ginsenoside Rg1 of the present invention, it is possible to being present in skin Psoriasin effect suppress.
Therefore, the Dermatologic preparation composition of the present invention can suppress the skin induced because of psoriasin Horn cell abnormal phenomena, recovers skin barrier in damaged condition, prevents and alleviates dermatosis, carrying simultaneously Rise moisturizing power and the restoring force of skin.
Accompanying drawing explanation
Fig. 1 is shown in psoriasin under the outside stimuluss such as UV-B, staphylococcus, tretinoin The chart of mrna expression amount.
Fig. 2 a is shown in Keratin 1 and Keratin 10 under ultraviolet light,long wave and UV-B outside stimulus The chart of mrna expression amount.
Fig. 2 b is shown in the mRNA table of Keratin 1 and Keratin 10 under staphylococcus outside stimulus The chart of the amount of reaching.
Fig. 2 c is shown in Keratin 1 and the mrna expression of Keratin 10 under tretinoin outside stimulus The chart of amount.
Fig. 3 a is shown in the chart of the mrna expression amount of Keratin 1 under psoriasin effect and shows Show the Western blotting result of protein expression amount.
Fig. 3 b is shown in the chart of the mrna expression amount of Keratin 10 under psoriasin effect and shows Show the Western blotting result of protein expression amount.
Fig. 4 is shown in interleukin-6 (IL-6), ginsenoside Rg1, IL-6+ ginsenoside Rg1 The chart of the mRNA amount of the psoriasin given expression to respectively under effect.
Fig. 5 a is shown in psoriasin, psoriasin+ginsenoside Rg1 gives expression under acting on respectively The chart of the mRNA amount of Keratin 1.
Fig. 5 b is shown in psoriasin, psoriasin+ginsenoside Rg1 gives expression under acting on respectively The chart of the mRNA amount of Keratin 10.
Fig. 6 is that artificial skin is expressed under psoriasin, psoriasin+ginsenoside Rg1's effect respectively The observation photo of the Keratin 1 gone out.
Fig. 7 is to use the skin preparations for extenal use comprising or not comprising ginsenoside Rg1 and using general skin In the case of external preparation, the contrast chart of skin moisture content.
Detailed description of the invention
Present inventor considered that when using the material that can suppress psoriasin effect to manufacture skin preparations for extenal use group During compound, can not only prevent and alleviate various dermatosis, additionally it is possible to promote skin self further Restoring force and moisturizing power, thus keep more beautiful skin.Therefore, by various candidate substances After carrying out screening and have passed through failure repeatedly and unremitting effort, finally it is found that ginsenoside Rg1 Psoriasin effect can be played the best inhibition.
Above-mentioned ginsenoside Rg1 is the soap included in the Radix Ginseng extract of structure shown in following chemical formula 1 One in glycosides composition:
<chemical formula 1>
Ginsenoside not only with more than 750 kinds of other plants included in the chemical constitution of saponin and pharmacology effect Can be different, its property of medicine the most as mild as a dove and there will not be any toxicity when being excessively used, and hardly Cause the generation of any haemolysis, therefore the skin preparations for extenal use group comprising ginsenoside Rg1 of the present invention Compound is expected to the most securely and effectively to be used.
Above-mentioned ginsenoside Rg1 can extract from plant, it is also possible to utilizes method known to corresponding industry Carry out synthesis to use, it is also possible to buy business commercially available prod and use.Usually from Radix Ginseng carry out extraction and Gathering, the Radix Ginseng kind now used there is no particular restriction, uses fresh ginseng, Radix Ginseng Rubra, Radix Ginseng, too Pole ginseng, tail ginseng etc. are advisable.Additionally, in above-mentioned extraction process, it is possible to use the stem of Radix Ginseng, root, leaf, All parts of the Radix Ginsengs such as flower, fruit, are not limited to the extract of certain specific part.
In the present invention, the content ratio of ginsenoside Rg1 is, Dermatologic preparation composition overall weight 0.001～5 weight %.
Comprise the Dermatologic preparation composition of ginsenoside Rg1 as above by being present in skin Antibacterial peptide in one i.e. psoriasin suppress, effectively prevent from causing because of above-mentioned psoriasin Skin keratinocytes form abnormal phenomena, and prevent or alleviate dermatosis whereby, in lifting skin Moisture.
Now, above-mentioned Dermatologic preparation composition can also comprise flavonoid substances (flavonoid).
The compositions of the present invention, can be dermatological composition, cleansing composition and cosmetic combinations More than one in thing are advisable.Additionally, the compositions of the present invention can comprise ginsenoside Rg1 or comprise people The extract of ginseng saponin Rg1 and other additives etc., also comprise permission in department of dermatologry and/or cosmetics The carrier used is advisable.
In applicable another embodiment of the present invention, ginsenoside Rg1 or comprise the extraction of ginsenoside Rg1 Take thing, it is also possible to be converted to the preparations such as dietary supplement compositions.
For being suitable for the dosage form of the compositions of the present invention, there is no particular restriction, can be suitable for and comprise cosmeceutical Or Dermatology is allowed medium or the dosage form of base material of use.This comprises be suitable for that local uses all Dosage form, such as solution, gel, solid, the anhydrous product of pasty state, is distributed to grease in watery thing Obtained Emulsion, suspension, microemulsion, microencapsulation, minitype particle or ion-type (liposome) And nonionic folliculus dispersant form or facial cream, skin cream, emulsion, powder, ointment, spray or Hide the forms such as flaw rod.Moreover, it is also possible to take foam (foam) form or comprise the aerosol of compression accelerator Agent (aerosol) compositions form.
These compositionss can manufacture according to the conventional method in corresponding field.In more detail, can adopt Take ointment, facial cream, gel, ointment (salves), essence (serums), Emulsion, aqueous solution, Powder, the form such as bar-shaped.
Additionally, the compositions of the present invention can include fatty material, organic solvent, lytic agent, concentrating agents, Gellant, softening agent, antioxidant, suspending agent, stabilizer, foaming agent (foaming agent), Aromatic, surfactant, water, ion-type or nonionic emulsifier, filler, metal ion envelope Lock agent (metal ion blocking agent) such as ethylenediaminetetraacetic acid (EDTA； Ethylenediaminetetraacetic acid), chelating agen (chelating agent), preservative agent, vitamin, Blocker (blocker), wetting agent, required oil divide, dyestuff, pigment, hydrophilic or lipophile activating agent, Other compositions any commonly used in lipid folliculus or cosmetics etc. are in cosmeceutical or Dermatology field Conventional use of adjuvant.The addition of above-mentioned adjuvant is cosmeceutical or Dermatology field routine makes Amount.
Additionally, the compositions of the present invention is in order to promote its skin improvement effects, it is also possible to comprise skin absorption Promote material.
Following for helping the understanding of the present invention, the most representational embodiment etc. will be illustrated. The interest field of the present invention is not limited to this, comprises all equivalency range.
In all accompanying drawings used in this manual, ginsenoside RG1 (Ginsenoside Rg1) Be expressed as G_Rg1, psoriasin (psoriasin, S100A7) is expressed as S100A7, Keratin 1 (keratin 1) be expressed as KRT 1, Keratin 10 (keratin 10) is expressed as KRT 10, staphylococcus aureus (Staphylococcus aureus) is expressed as S.aureus, tretinoin (retinoic acid) is expressed as RA, Ultraviolet light,long wave is expressed as UVA, UV-B is shown as UVB, RT-polymerase chain reaction (RT-PCR) Correction benchmark mRNA (control) or correction dbt protein (control) table of Western blotting It is shown as con.
Confirm whether psoriasin can induce skin keratin and form exception
Since it is considered that the psoriasin in skin keeps in the dermatosis such as atopic dermatitis and psoriasis The phenomenon of higher concentration, confirms in experimental example 1 to 3 whether outside stimulus can again result in general skin The increase of psoriasis concentration in skin, and observe formed above-mentioned psoriasin time occurred with skin angle The various changes that the formation of matter is correlated with.
The type that said external stimulates is, ultraviolet light,long wave or B, staphylococcus and tretinoin.
[experimental example 1] psoriasin expression change under outside stimulus confirms
In order to the change of the psoriasin expression under outside stimulus is confirmed, first to skin angle Cell plastid is cultivated.As first step, will be formed carefully by isolated cutin from neonatal epidermis Born of the same parents are with 1.25 × 106The density of individual cell/culture dish is inoculated into the Tissue Culture Dish (cell of a diameter of 60mm Culture dish) KGM culture medium in.Next CO is utilized2Above-mentioned Tissue Culture Dish is existed by incubator 37 DEG C, 5%CO2Under the conditions of carry out keeping, by keratinocyte cultivate to about 80% coverage density (confluency)。
It follows that the above-mentioned keratinocyte turned out to be divided into three experimental grouies, then as outward Portion stimulates means to be utilized respectively UV-B 25mJ/cm2, staphylococcus 6 μ g/ml, tretinoin 1 μM carry out After process, then carry out the cultivation of 2 days.It follows that isolate the culture fluid not having cell, then profit By enzyme linked immunosorbent assay (ELISA assay), the mrna expression amount of psoriasin is measured and fixed Quantify.As correction benchmark mRNA, use housekeeping gene (housekeeping gene) RPL13A.
Said determination result is as shown in Figure 1.Above-mentioned in all experimental grouies that outside stimulus processes, The mrna expression amount of its psoriasin all increased.
[experimental example 2] confirms whether outside stimulus can induce skin keratin and form exception
In order to confirm whether outside stimulus can induce skin keratin and form exception, in epidermal differentiation protein Representational Keratin 1 and the mRNA of Keratin 10 and the change of protein expression amount are analyzed. Above-mentioned Keratin 1 and Keratin 10 are used as the index that cutin is formed.
The stage cultivating skin keratinocytes is identical with above-described embodiment 1.It follows that will be trained The above-mentioned keratinocyte raised is divided into several experimental grouies, then as outside stimulus means profit respectively By ultraviolet, staphylococcus, tretinoin, it is processed.Specifically, ultraviolet light,long wave is being utilized 10mJ/cm2, UV-B 20mJ/cm2, staphylococcus 3 μ g/ml, staphylococcus 6 μ g/ml, tretinoin After 1 μM processes, then carry out the cultivation of 2 days.
It follows that carry out mRNA analysis or protein analysis.Describe in detail as follows.
1) mRNA analyzes
After removing the culture medium of the above-mentioned cell turned out, by adding the Trizol reagent of 1ml The mRNA of glial cell is separated by (Trizol, invitrogen), then utilizes ultraviolet detector The mRNA of above-mentioned glial cell is carried out under the conditions of 260nm by (HEWLLETT PACKARD) Quantitatively.It follows that by RT-polymerase chain reaction (RT-PCR；reverse Transcription-polymerase chain reaction) to the Keratin 1 in the mRNA of glial cell with And the mrna expression amount of Keratin 10 is confirmed.Now as correction benchmark mRNA, use Housekeeping gene RPL13A.
Experimental result is as shown in Fig. 2 a, Fig. 2 b and Fig. 2 c.Experiment after processing through outside stimulus In group, the gene expression of Keratin 1 and Keratin 10 has reduced.
2) protein analysis
By adding RIPA buffer (Radio-immunoprecipitation to the above-mentioned cell turned out Assay buffer), make protein dissolution.It follows that utilize SDS-PAGE that above-mentioned protein is carried out Separate, then carried out really by Western blotting (Western blot) keratin 1 and Keratin 10 Recognize and quantification.Now as correction dbt protein, use the glyceraldehyde-3-given expression to from housekeeping gene Phosphate dehydrogenase (GAPDH；Glyceraldehyde 3-phosphate dehydrogenase).
Experimental result shows, after processing through outside stimulus, and Keratin 1 and the egg of Keratin 10 White matter expression presents the minimizing phenomenon identical with mrna expression amount.
[experimental example 3] confirms whether psoriasin can induce skin keratin and form exception
Summary embodiment 1 and the result of embodiment 2, in order to examine whether psoriasin can induce skin Skin cutin forms exception, implements experimental example 3.
The implementation process of the present embodiment 3 is identical with above-described embodiment 2, simply by right in above-described embodiment 2 The keratinocyte cultivated carries out the outside stimulus processed, and replaces to add 0.25 μ g/ml, 1 μ g/ml Psoriasin after carry out the cultivation of 4 days again.
Experimental result is as shown in Fig. 3 a and Fig. 3 b.In psoriasin processes experimental group, Keratin 1 And the mRNA of Keratin 10 and protein expression amount have reduced.
The psoriasin inhibition of ginsenoside Rg1 confirms
By above-described embodiment 1 to 3, have confirmed that psoriasin is that skin keratin forms abnormal evocator One of matter.Below, the embodiment of the psoriasin inhibitory action for confirming ginsenoside Rg1 is carried out Explanation.
The psoriasin inhibition-1 of [embodiment 1] ginsenoside Rg1
The stage cultivating skin keratinocytes is identical with above-described embodiment 1.It follows that will be trained The above-mentioned cell raised is divided into two experimental grouies, then utilizes the known psoriasin of 1 μ g/ml to express and lures Lead material i.e. interleukin (IL-6；Interlukine-6) one of them experimental group is processed, then Another experimental group is processed by the ginsenoside Rg1 simultaneously utilizing IL-6 and 10ppm of 1 μ g, Carry out the cultivation of 2 days the most again.Wherein, above-mentioned ginsenoside Rg1 is the psoriasin that IL-6 is induced The candidate substances of expression inhibiting.
After 2 days, remove culture medium, then utilize identical with the mRNA analysis in above-described embodiment 2 Method it is carried out mRNA analysis, the then mRNA to the psoriasin in above-mentioned two experimental group Expression difference is confirmed.
Experimental result is as shown in Figure 4.Relative to only adding the experimental group of IL-6, utilize at the same time IL-6 with And ginsenoside Rg1 carries out in the experimental group processed, the mrna expression amount of psoriasin has reduced.
The psoriasin inhibition-2 (external) of [embodiment 2] ginsenoside Rg1
The stage cultivating skin keratinocytes is identical with above-described embodiment 1.It follows that will be trained The above-mentioned cell raised is divided into two experimental grouies, then utilizes the psoriasin of 1 μ g/ml to one of them Experimental group processes, then utilizes psoriasin and the ginsenoside Rg1 of 10ppm of 1 μ g/ml simultaneously Another experimental group is processed, carries out the cultivation of 4 days the most again.After incubation according to above-mentioned enforcement MRNA in example 2 analyzes and protein analysis method, keratin 1 and Keratin 10 MRNA and protein expression amount confirm.
Experimental result is as shown in Fig. 5 a and Fig. 5 b.As shown in above-mentioned Fig. 5 a and Fig. 5 b, in only profit Carry out in the experimental group processed with psoriasin, Keratin 1 (KRT 1) and Keratin 10 (KRT 10) Expression reduced, but utilize ginsenoside Rg1 and psoriasin to carry out the experiment processed at the same time In group, present the mrna expression amount of higher KRT 1 and KRT 10.Additionally, it is sharp at the same time Carry out in the experimental group processed with ginsenoside Rg1 and psoriasin, the mrna expression of its KRT 1 Amount level is similar with undressed experimental group, but the mrna expression amount of KRT 10 on the contrary higher than without The experimental group processed.
The psoriasin inhibition-3 (artificial skin) of [embodiment 3] ginsenoside Rg1
In order to confirm with the effect under experiment in vivo like environment, utilize artificial skin (MaTack Company) tested.
The epidermis upper layer part of one of them experimental group is processed by the psoriasin utilizing 2 μ g/ml, and profit With the psoriasin of 2 μ g/ml and the ginsenoside Rg1 of 10ppm, another experimental group is processed, Within 1 week, carry out amounting to 3 times process every 2 days.It follows that utilize formalin to two Individual experimental group is fixed, and keratin 1 has carried out immunostaining process.
Keratin 1 after dyed process is rendered as redness, and its observed result is as shown in Figure 6.Relatively In undressed experimental group, carrying out in the experimental group processed merely with psoriasin, Keratin 1 Expression has reduced, and skin barrier collapse causes organizational structure loose.But utilize Corii Bovis seu Bubali at the same time Tinea element and ginsenoside Rg1 carry out in the experimental group processed, the expression of Keratin 1 and skin barrier Structure recover normal.
[embodiment 4]
Below, based on the psoriasin inhibition of above-mentioned ginsenoside Rg1, it is prepared for such as table 1 The compositions of the shown present invention.
Table 1
* comparing dosage form example and implement its content of numeric representation of dosage form example, unit is weight %.
Manufacture and do not comprise the comparison dosage form example 1 of ginsenoside Rg1 and comprise ginsenoside with 0.1 weight % The skin preparations for extenal use of the enforcement dosage form example 1 of Rg1, with 30～49 years old 40 women (4 experimental grouies, Often organize 10 people) it is object so that it is and every morning within 8 week and evening are by above-mentioned skin preparations for extenal use Spread upon face.On pretreatment (0 week), after 4 weeks, after 8 weeks, measure each experimental group in three times Skin moisture content, the meansigma methods comparing result of said determination is as shown in Figure 7.
When measuring the moisture in skin, use can be to keratodermatitis moisture (hydration) moisture of skin that dielectric constant (dielectric constant) changing value is measured is surveyed Examination instrument (Corneometer).
Measurement result shows, uses the skin moisturization during skin preparations for extenal use comprising ginsenoside Rg1 Apparently higher than the situation using the skin preparations for extenal use not comprising ginsenoside Rg1.
Based on above-described embodiment, can confirm that the Dermatologic preparation composition of the present invention is expected to can be right The dermatosis such as atopic dermatitis or psoriasis provides skin care and recovery effects.

Claims (8)

1. a Dermatologic preparation composition, it is characterised in that: effective ingredient comprises ginsenoside Rg1.
Dermatologic preparation composition the most according to claim 1, it is characterised in that:
The structure of described ginsenoside Rg1 is as shown in following chemical formula 1:
<chemical formula 1>
Dermatologic preparation composition the most according to claim 1 and 2, it is characterised in that:
The content of described ginsenoside Rg1 is the 0.001～5 of described Dermatologic preparation composition overall weight Weight %.
Dermatologic preparation composition the most according to claim 1, it is characterised in that:
Described ginsenoside Rg1 can suppress the expression of psoriasin.
Dermatologic preparation composition the most according to claim 1, it is characterised in that:
Described Dermatologic preparation composition is used for preventing or alleviating dermatosis.
Dermatologic preparation composition the most according to claim 1, it is characterised in that:
Described Dermatologic preparation composition is used for skin moisture-keeping.
Dermatologic preparation composition the most according to claim 5, it is characterised in that:
Described dermatosis comprises atopic dermatitis or psoriasis.
Dermatologic preparation composition the most according to claim 1, it is characterised in that:
Described Dermatologic preparation composition comprises dermatological composition, cleansing composition and cosmetics More than one in compositions.
CN201610195635.0A 2015-03-31 2016-03-31 Skin external preparation comprising ginsenoside Rg1 Pending CN105997842A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0045560 2015-03-31
KR1020150045560A KR20160117015A (en) 2015-03-31 2015-03-31 SKIN EXTERNAL PREPARATION COMPRISING GINSENOSIDE Rg1

Publications (1)

Publication Number Publication Date
CN105997842A true CN105997842A (en) 2016-10-12

Family

ID=57080983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610195635.0A Pending CN105997842A (en) 2015-03-31 2016-03-31 Skin external preparation comprising ginsenoside Rg1

Country Status (2)

Country Link
KR (1) KR20160117015A (en)
CN (1) CN105997842A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074131A1 (en) * 2017-10-15 2019-04-18 株式会社パークフォレスト Antiallergic agent including panax ginseng extract extracted using silicate
CN109908161A (en) * 2019-04-03 2019-06-21 上海中医药大学附属曙光医院 Application of the Ginsenoside compound K in preparation treatment atopic dermatitis external drug

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116672352B (en) * 2023-06-26 2024-04-19 珍卡儿药妆有限公司 Pharmaceutical composition for eczema and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100302063B1 (en) * 1997-08-01 2001-10-26 박호군 Complement activity controlling agent containing ginseng saponin and sapogenin
CN101217999A (en) * 2005-07-08 2008-07-09 宝洁公司 Personal care compositions and methods for the beautification of mammalian skin and hair
WO2008125231A1 (en) * 2007-04-17 2008-10-23 Bayer Consumer Care Ag Ginsenosides and extracts containing them combined with dexpanthenol
CN101443025A (en) * 2006-05-17 2009-05-27 拜耳消费者保健股份公司 Use of ginsenosides and extracts containing them
CN102961296A (en) * 2012-12-19 2013-03-13 成都山信药业有限公司 Composition with skin whitening function and application of composition
KR101345226B1 (en) * 2013-07-31 2013-12-26 충남대학교산학협력단 Novel paenibacillus sp. mbt213, fermented ginseng using the same and composition comprising extract of fermented ginseng using the same for preventing or treating atopic dermatitis
CN103565679A (en) * 2012-07-19 2014-02-12 郑毅男 Fresh ginseng extract preparation method and application of fresh ginseng extract in cosmetics
CN103919697A (en) * 2013-01-14 2014-07-16 汕头市雅娜化妆品实业有限公司 Skin aging resistance traditional Chinese medicine cosmetic and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102021463B1 (en) 2013-04-24 2019-09-16 (주)아모레퍼시픽 External composition for skin containing Ginsenoside Rg3

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100302063B1 (en) * 1997-08-01 2001-10-26 박호군 Complement activity controlling agent containing ginseng saponin and sapogenin
CN101217999A (en) * 2005-07-08 2008-07-09 宝洁公司 Personal care compositions and methods for the beautification of mammalian skin and hair
CN101443025A (en) * 2006-05-17 2009-05-27 拜耳消费者保健股份公司 Use of ginsenosides and extracts containing them
WO2008125231A1 (en) * 2007-04-17 2008-10-23 Bayer Consumer Care Ag Ginsenosides and extracts containing them combined with dexpanthenol
CN103565679A (en) * 2012-07-19 2014-02-12 郑毅男 Fresh ginseng extract preparation method and application of fresh ginseng extract in cosmetics
CN102961296A (en) * 2012-12-19 2013-03-13 成都山信药业有限公司 Composition with skin whitening function and application of composition
CN103919697A (en) * 2013-01-14 2014-07-16 汕头市雅娜化妆品实业有限公司 Skin aging resistance traditional Chinese medicine cosmetic and preparation method thereof
KR101345226B1 (en) * 2013-07-31 2013-12-26 충남대학교산학협력단 Novel paenibacillus sp. mbt213, fermented ginseng using the same and composition comprising extract of fermented ginseng using the same for preventing or treating atopic dermatitis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANG-EUI HONG等: "Anti-inflammatory and Anti-oxidative Effects of Korean Red Ginseng Extract in Human Kerati", 《IMMUNE NETWORK》 *
YOUNG-WOOK SHIN等: "Inhibitory Effect of Protopanxatriol Ginsenosides in an Oxazolone-induced Mouse Psoriatic Model", 《J. GINSENG RES.》 *
李慧萍: "人参AFG系列化妆品开发研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *
李慧萍: "人参AFG系列化妆品开发研究", 《中国优秀硕士学位论文全文数据库（电子期刊）》 *
黎月桃: "三七乳膏的制备及体外透皮特性的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074131A1 (en) * 2017-10-15 2019-04-18 株式会社パークフォレスト Antiallergic agent including panax ginseng extract extracted using silicate
JPWO2019074131A1 (en) * 2017-10-15 2020-12-17 株式会社パークフォレスト Anti-allergic agent containing ginseng extract extracted with silicate
JP7249036B2 (en) 2017-10-15 2023-03-30 株式会社パークフォレスト Antiallergic agent containing Korean ginseng extract extracted using silicate
CN109908161A (en) * 2019-04-03 2019-06-21 上海中医药大学附属曙光医院 Application of the Ginsenoside compound K in preparation treatment atopic dermatitis external drug

Also Published As

Publication number Publication date
KR20160117015A (en) 2016-10-10

Similar Documents

Publication Publication Date Title
US20090142285A1 (en) Cosmetic composition comprising ascorbic acid 2-glucoside and ergothioneine
CN102026616B (en) Substances that increase the activation threshold of immune cells
CN104138346A (en) Anti-wrinkle cosmetic composition and preparation method thereof
CN105997842A (en) Skin external preparation comprising ginsenoside Rg1
EP3102181B1 (en) Active complex for a skin anti-ageing cosmetic
JP4469633B2 (en) Skin aging prevention / improving agent
JP5921056B2 (en) Cosmetic composition
CN111148504A (en) Skin external composition containing 1,2,3,4,6-penta-O-galloyl- β -D-glucose for moisturizing skin
EP2986983B1 (en) Use of barrier biomarkers for evaluating the effectiveness of active ingredients
KR101837446B1 (en) Composition for improving skin wrinkle or skin moisturing comprising alpha-, beta-, gamma-mangostin or gartanin compound as effective component
EP3338759A1 (en) Vesicles containing saccharide isomerate, hydrolyzed lupine protein, and intercorneocyte lipid mimetics as active ingredient, and composition for skin external application comprising the same
JP2013193985A (en) Hair tonic
TWI729618B (en) Use of phalaenopsis plant extract for anti-glycation and improving skin appearance
US10117827B2 (en) Preparations for suppressing or attenuating ocular irritancy
KR20200137431A (en) Composition for skin anti-inflammation and skin moisturizing comprising artemisia extract extracted with skin cosmetic solution as a solvent
EP2040803B1 (en) Use of a cosmetic composition for combating the effects of electromagnetic waves on the skin
TWI809308B (en) Use of wasabia japonica leaves for inhibiting the production of acne and reducing cutibacterium acnes secretions
US10391050B2 (en) Dermatological, cosmetic or cosmeceutical compositions intended for skin treatment
KR102119466B1 (en) Screening method for material for restoring inhibition of differentiation of keratinocytes by fine particulate matter and composition for restoring inhibition of differentiation of keratinocytes by fine particulate matter
DE102014113861B4 (en) Bioactive component for use in combating lung tumor metastasis
TWI687237B (en) Use of extract of victoria cruziana for inducing expression of keratin gene and hyaluronan synthase 2 gene, and enhancing moisture-retaining capacity of skin
Prokofiev et al. Solid herbal extract of Primula veris L. improves morphofunctional condition of rats’ myocardium in chronic alcohol intoxication
KR101862314B1 (en) Composition for improvement effect vitality of skin and hair, manufacturing process for the same
JP2010065007A (en) Claudin-1 production promoter and skin barrier function improving agent
CN108883142B (en) Bioactive compositions from ginseng plant (PANAX SPP.) and methods of making and using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1226630

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161012

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1226630

Country of ref document: HK